Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 4 3Phase 2/3 1Phase 1/2 1

Status

Completed 4Recruiting 3Terminated 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

NET 2Endocrine 2Gynecologic 1

Conditions

Neuroendocrine Tumors 2Serotonin Syndrome 1Peritoneal Neoplasms 1Intestinal Obstruction 1Flushing 1Endocrine Tumors 1Diarrhea 1Carcinoma 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × lanreotide × Clear all
NCT00353496 2025-03-05

CLARINET

Ipsen

Phase 3 Completed
264 enrolled 17 charts

Endocrine Tumors

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

Ipsen

Phase 3 Completed
89 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Ipsen

Phase 3 Completed
80 enrolled
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡